Molecular structure of AZT
Find information on thousands of medical conditions and prescription drugs.

Zidovudine

Zidovudine (INN) or azidothymidine (AZT) is an antiretroviral drug, the first one approved for treatment of HIV. It is also sold under the names Retrovir® and Retrovis®, and as an ingredient in Combivir® and Trizivir®. It is an analog of thymidine. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

History

Zidovudine was the first drug approved for the treatment of AIDS and HIV infection. Jerome Horowitz first synthesized AZT in 1964, under a US National Institutes of Health (NIH) grant. It was originally intended to treat cancer, but failed to show efficacy and had an unacceptably high side effect profile. The drug then faded from view until February 1985, when Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan, three scientists in the National Cancer Institute (NCI), collaborating with scientists in Burroughs Wellcome Co., started working on it as an AIDS drug. After showing that this drug worked against HIV in the test tube, the team conducted the initial clinical trial that provided evidence that it could increase CD4 counts in AIDS patients. Like other reverse transcriptase inhibitors, AZT inhibits HIV replication by blocking the action of reverse transcriptase, the enzyme that HIV uses to replicate its RNA for splicing into the DNA of a target cell.

A placebo-controlled randomized trial of AZT was subsequently conducted by Burroughs-Wellcome (now GlaxoSmithKline), in which it was shown that it could prolong the life of patients with AIDS. Burroughs Wellcome Co. filed for a patent on AZT in 1986. The Food and Drug Administration (FDA) approved the drug (via the then-new FDA accelerated approval system) for use against HIV, AIDS, and AIDS Related Complex (ARC, a now-defunct medical term for pre-AIDS illness) on March 20, 1987, and then as a preventive treatment in 1990. It was initially administered in much higher dosages than today, typically one 400mg dose every four hours (even at night). However, the unavailability at that time of alternatives to treat AIDS affected the risk/benefit ratio, with the certain toxicity of HIV infection outweighing the risk of drug toxicity. One of AZT's side-effects includes anemia, a common complaint in early trials.

Modern treatment regimens typically use lower dosages two to three times a day in order to improve the overall quality of life. Like other antiretroviral drugs, AZT is also almost always used in highly active antiretroviral therapy (HAART). That is, it is combined with other drugs in order to prevent mutation of the HIV into an AZT-resistant form.

The crystal structure of AZT was reported by Alan Howie (Aberdeen University) in 1988. In the solid state AZT forms a hydrogen bond network. Note that AZT is based upon a sugar.

Treatment

When used as a preventative treatment, AZT has proven to be particularly effective. If treatment is started before the total amount of virus, known as the viral load, reaches a critical point of 50 million parts per millilitre of blood serum, the chance of AIDS developing is effectively zero. This is widely used with medical practitioners who receive accidental infections (please see discussion).

Read more at Wikipedia.org


[List your site here Free!]


Perinatal Zidovudine and Mitochondrial Defects.(Brief Article) : An article from: Family Practice News $5.95 Commentary. (Who pays for AZT? case study) : An article from: The Hastings Center Report $5.95
Treatment of HIV-positive pregnant women lowers infection risk of infants. (Digests). : An article from: International Family Planning Perspectives $5.95 Vical lands major contract to develop AZT derivative. (company profile) : An article from: San Diego Business Journal $5.95
Journal of the American Medical Association: "Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African Setting: a randomized ... An article from: Studies in Family Planning $5.95 Progress reports in the battle against acquired immune deficiency syndrome. (toll-free AIDS information, zidovudine for pregnant women, antigen test for HIV-1) : An article from: FDA Consumer $5.95
Short Anti-HIV Treatment Okay for Infant If Mother Receives Standard Regimen.(Brief Article) : An article from: International Family Planning Perspectives $5.95 AZT Trials and Tribulations. : An article from: The Hastings Center Report $5.95
Zidovudine in First Trimester Not Linked to Higher Risk of Birth Defects.(Brief Article)(Statistical Data Included) : An article from: Family Practice News $5.95 Zidovudine hyperpigmentation mainly in blacks.(Infectious Diseases) : An article from: Internal Medicine News $5.95

L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine
Moretti S, Famularo G, Marcellini S, et al. Antioxid Redox Signal 2002;4:391-403. Apoptosis is critical to the progression of human immunodeficiency ...
Stability of Zidovudine and Ranitidine in 0.9% Sodium Chloride and 5% Dextrose Injections Stored at Ambient Temperature (23 ±2°C) and 4°C
Abstract The stability of a 2-mg/mL zidovudine and 0.5-mg/mL ranitidine admixture stored in 0.9% sodium chloride and 5% dextrose injections in 50-mL polyvinylchloride ...
Stability of Zidovudine and Dobutamine Hydrochloride Injections in 0.9% Sodium Chloride and 5% Dextrose Injections Stored at Ambient Temperature (23 ±2°C)
Abstract The stability of a 2-mg/mL zidovudine and 1-mg/mL dobutamine hydrochloride admixture stored in 0.9% sodium chloride and 5% dextrose injections ...
Aurobindo Pharma
Aurobindo Pharma.(gets approval to market generic version of Retrovir's zidovudine oral solution)
Zidovudine Not Linked to Mitochondrial Defects
Over 1,000 HIV-negative children examined. SAN FRANCISCO -- Perinatal exposure to zidovudine was not associated with mitochondrial defects in early ...
Perinatal Zidovudine and Mitochondrial Defects - Brief Article
SAN FRANCISCO -- Perinatal exposure to zidovudine was not associated with mitochondrial defects in early childhood in a review of more than 1,000 HIV-negative ...
Zidovudine in First Trimester Not Linked to Higher Risk of Birth Defects - Brief Article - Statistical Data Included
SAN FRANCISCO -- Zidovudine monotherapy during the first trimester of pregnancy does not appear to increase the risk of birth defects detected at the ...
ZIDOVUDINE - Retrovir
Zidovudine is supplied most commonly in film-coated tablets (300 mg, biconvex, round and white) with "GXCW3" on one side and "300" on the other. The ...

Home Contact Resources Exchange Links ebay